Absolute benefits of empagliflozin in type 2 diabetes: a game changer?

Postgrad Med J. 2017 Jul;93(1101):373-375. doi: 10.1136/postgradmedj-2016-134741. Epub 2017 Apr 22.
No abstract available

Keywords: All-cause-mortality; EMPA-REG OUTCOME trial; Empagliflozin; NNT/year; SGLT2 inhibitor; Type 2 diabetes.

Publication types

  • Editorial

MeSH terms

  • Benzhydryl Compounds / therapeutic use*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / mortality
  • Glucosides / therapeutic use*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Substances

  • Benzhydryl Compounds
  • Glucosides
  • Hypoglycemic Agents
  • empagliflozin